MANNATECH INC

Listed Company

MTEXCIK 0001056358NasdaqNon-AcceleratedSmaller ReportingMedicinal Chemicals & Botanical ProductsTexasFY ends Dec 31

Period

FY 2025

Revenue

$108.00M

Net Income

$-15.21M

Total Assets

$29.99M

Equity

$-5.22M

Shares Out

1.93M

Op. Cash Flow

$-2.96M

Business

MANNATECH INC is a global wellness solution provider that develops and sells proprietary nutritional supplements, skin care, anti‑aging and weight‑management products. Its main products include Ambrotose® complex and Manapol® powder, Ambrotose Life®, TruHealth™ system, Omega‑3 with Vitamin D3, EMPACT+, Glyco‑based supplements, Luminovation skincare and a range of targeted and essentials formulations. The company operates a single reporting segment focused on proprietary product development and sales through a network marketing distribution model and a non‑direct cross‑border e‑commerce subsidiary in China (Meitai). It markets and distributes products across the Americas, EMEA and Asia/Pacific via independent associates, preferred customers, e‑commerce and direct shipments to additional countries.

Summary from filing dated 2025-03-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	108	118	132	137	160
Cost of sales	27	26	29	33	34
Gross profit	81	91	103	104	126
Commissions and incentives	42	48	—	—	—
Selling and administrative expenses	40	42	—	—	—
Total operating expenses	81	90	104	105	117
(Loss) income from operations	−426,000	1	−964,000	−405,000	9
Interest expense, net	−406,000	−279,000	—	—	—
Other Nonoperating Income (Expense)	−2	3	−170,000	−162,000	−223,000
(Loss) income before income taxes	−3	4	—	—	—
Income tax expense	−12	−1	−1	−4	950,000
Net (loss) income	−15	2	−2	−4	10
Basic (in dollars per share)	−8	1.32	−1.2	−2.35	4.95
Diluted (in dollars per share)	−8	1.32	−1.2	−2.35	4.71
Basic (in shares)	2	2	2	2	2
Diluted (in shares)	2	2	2	2	2

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	6	11	8	14	24
Restricted cash	550,000	550,000	938,000	944,000	944,000
Accounts receivable, net of allowance for credit losses of $756 and $935 as of December 31, 2025 and 2024, respectively	1,000	19,000	100,000	200,000	100,000
Income tax receivable	736,000	737,000	465,000	423,000	342,000
Inventories, net	10	10	15	15	12
Prepaid expenses and other current assets	2	2	2	2	3
Deferred commissions	1	1	—	—	—
Total current assets	21	26	28	35	43
Property, Plant and Equipment with Construction in Progress, Net	3	3	—	—	—
Operating lease right-of-use assets	3	2	3	—	—
Other assets	3	3	4	8	9
Deferred tax assets, net	0	2	2	—	—
Long-term restricted cash	234,000	569,000	—	—	—
Total assets	30	36	41	49	60
Commissions and incentives payable	7	9	8	9	10
Accrued expenses	3	4	5	8	9
Deferred revenue	3	3	—	—	—
Accounts payable	2	2	4	4	4
Current portion of operating lease liabilities	2	1	2	—	—
Taxes payable	1	2	2	3	2
Current notes payable	0	100,000	200,000	300,000	200,000
Current portion of finance lease liabilities	293,000	275,000	—	—	—
Total current liabilities	19	21	26	30	30
Long-term notes payable, excluding current portion	3	3	0	—	—
Operating lease liabilities, excluding current portion	2	2	3	—	—
Other Liabilities, Noncurrent	1	1	1	5	5
Finance lease liabilities, excluding current portion	388,000	680,000	956,000	—	—
Deferred tax liabilities, net	10	0	—	—	3,000
Total liabilities	35	27	31	35	35
Commitments and contingencies (Note 13)	—	—	—	—	—
Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding	0	0	0	0	0
Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and 1,900,930 shares outstanding as of December 31, 2025 and 2,742,857 shares issued and 1,884,814 shares outstanding as of December 31, 2024	0	0	0	0	0
Additional paid-in capital	33	33	33	33	33
Retained earnings (accumulated deficit)	−14	1	−1	2	8
Accumulated other comprehensive loss	−5	−6	−1	−208,000	2
Treasury stock, at average cost, 841,927 shares as of December 31, 2025 and 858,043 shares as of December 31, 2024	−20	−20	—	—	—
Total shareholders equity	−5	9	10	14	24
Total liabilities and shareholders equity	30	36	41	49	60

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	1	2	2	—	—
Non-cash operating lease expense	2	2	—	—	—
Provision for inventory losses	120,000	777,000	463,000	543,000	638,000
Recoveries in current period	−128,000	−312,000	519,000	−26,000	246,000
Loss on disposal of assets	0	2,000	7,000	3,000	36,000
Gain on disposal of subsidiary	0	−228,000	0	−23,000	0
Unrealized loss (gain) from foreign exchange	2	−3	—	—	—
Stock-based compensation expense	379,000	291,000	278,000	337,000	260,000
Deferred income taxes	12	−159,000	—	—	—
Accounts receivable	173,000	344,000	−391,000	−102,000	−150,000
Income tax receivable	4,000	−277,000	−42,000	−81,000	666,000
Inventories	313,000	2	−272,000	−3	169,000
Prepaid expenses and other current assets	835,000	2	1	1	144,000
Deferred commissions	−19,000	859,000	346,000	−107,000	−26,000
Other assets	−226,000	625,000	−226,000	768,000	486,000
Accounts payable	315,000	−2	−351,000	392,000	−828,000
Accrued expenses and other long-term liabilities	−3	−4	−2	−4	−2
Taxes payable	−781,000	451,000	−2	1	754,000
Commissions and incentives payable	−2	887,000	−1	−355,000	−1
Deferred revenue	58,000	−2	−320,000	239,000	−605,000
Net cash (used in) provided by operating activities	−3	2	−2	−3	11
Acquisition of property and equipment	−1	−297,000	−748,000	−1	−650,000
Proceeds from sale of assets	0	12,000	1,000	0	0
Net cash used in investing activities	−1	−285,000	−747,000	−1	−650,000
Proceeds from notes payable	0	4	—	—	—
Repayment of note payable	−234,000	0	—	—	—
Repayment of finance lease obligations and other financing obligations	−327,000	−2	—	—	—
Net cash (used in) provided by financing activities	−561,000	2	−2	−4	−9
Effect of currency exchange rate changes on cash and cash equivalents and restricted cash	−669,000	−809,000	—	—	—
(Decrease) increase in cash and cash equivalents and restricted cash	−6	3	−6	−10	−2
Income taxes paid, net	400,000	800,000	3	715,000	137,000
Interest paid on notes payable, finance leases and other financing obligations	512,000	475,000	—	—	—
Assets acquired through other financing arrangements	0	446,000	—	—	—
Operating lease right-of-use assets acquired in exchange for new operating lease liabilities	3	347,000	305,000	2	70,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro